

Aberystwyth University

VALIDATE

Fletcher, Helen A.; Chatterjee, Mitali; Cooper, Andrea; Hussell, Tracy; Kaye, Paul M.; Prior, Joann; Reljic, Rajko; Vermaak, Samantha; Vordermeier, Martin; Williams, Ann; McShane, Helen

Published in:
F1000Research

DOI:
[10.12688/f1000research.14386.1](https://doi.org/10.12688/f1000research.14386.1)

Publication date:
2019

Citation for published version (APA):

Fletcher, H. A., Chatterjee, M., Cooper, A., Hussell, T., Kaye, P. M., Prior, J., Reljic, R., Vermaak, S., Vordermeier, M., Williams, A., & McShane, H. (2019). VALIDATE: Exploiting the synergy between complex intracellular pathogens to expedite vaccine research and development for tuberculosis, leishmaniasis, melioidosis and leprosy. *F1000Research*, 7, [485]. <https://doi.org/10.12688/f1000research.14386.1>

Document License CC BY

General rights

Copyright and moral rights for the publications made accessible in the Aberystwyth Research Portal (the Institutional Repository) are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Aberystwyth Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Aberystwyth Research Portal

Take down policy


If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

tel: +44 1970 62 2400
email: is@aber.ac.uk



OPINION ARTICLE

VALIDATE: Exploiting the synergy between complex intracellular pathogens to expedite vaccine research and development for tuberculosis, leishmaniasis, melioidosis and leprosy [version 1; peer review: 3 approved]

Helen A. Fletcher ¹, Mitali Chatterjee², Andrea Cooper³, Tracy Hussell⁴, Paul M. Kaye⁵, Joann Prior⁶, Rajko Reljic⁷, Samantha Vermaak⁸, Martin Vordermeier⁹, Ann Williams¹⁰, Helen McShane⁸

- ¹The London School of Hygiene and Tropical Medicine, London, UK
- ²Department of Pharmacology, Institute of Postgraduate Medical Education & Research, Kolkata, India
- ³Department of Infection, Immunity and Inflammation, University of Leicester, Leicester, UK
- ⁴Manchester Collaborative Centre for Inflammation Research, University of Manchester, Manchester, UK
- ⁵Centre for Immunology and Infection, University of York, York, UK
- ⁶Defence Science and Technology Laboratory, Porton Down, UK
- ⁷Institute for Infection and Immunity, St George's University of London, London, UK
- ⁸The Jenner Institute, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK
- ⁹Department of Bacteriology, Animal and Plant Health Agency, Weybridge, UK
- ¹⁰National Infection Service, Public Health England, Porton Down, UK




V1 First published: 23 Apr 2018, 7:485 (<https://doi.org/10.12688/f1000research.14386.1>)
 Latest published: 23 Apr 2018, 7:485 (<https://doi.org/10.12688/f1000research.14386.1>)

Abstract

For several complex intracellular pathogens, we have an urgent need for effective vaccines and yet there are common barriers to vaccine development. These diseases, including tuberculosis, leishmaniasis, leprosy and melioidosis, cause a huge burden of disease and disproportionately affect low and middle income countries. They are therefore often neglected due to the marginalisation of affected populations and the poor predicted commercial return on investment. Barriers to vaccine development include an incomplete understanding of protective immunity and translation from the bench into clinical vaccine trials. The current linear approach to vaccine research and development for these pathogens, which involves basic research, vaccine design, and vaccine evaluation in preclinical challenge models and clinical trials, is inefficient for these complex intracellular pathogens. We have established a Global Challenges Research Fund Network for VAccine deveLopment for complex Intracellular neglecteD pATHogEns, “VALIDATE”, where we aim to adopt a more flexible, integrated cross-pathogen approach to accelerate vaccine research and clinical development for these four pathogens, by cross-pathogen analyses, cross-discipline collaborations, and repeated integration of data from human and animal studies. This network provides a unique opportunity to bring together individuals

Open Peer Review

Reviewer Status 

	Invited Reviewers		
	1	2	3
version 1			
published 23 Apr 2018	report	report	report
1	Antonio Campos-Neto , Detectogen Inc., Westborough, USA		
2	Lisa A. Morici , Department of Microbiology and Immunology, New Orleans, USA		
3	Steven G. Reed , Infectious Disease Research Institute, Seattle, USA		

Any reports and responses or comments on the article can be found at the end of the article.

working on four exemplar complex intracellular neglected pathogens (*M.tb*, *Leishmania* spp., *B. pseudomallei* and *M.leprae*), which share a common lifestyle as pathogens of macrophages, induce similar end-stage pathologies and alter host immune and metabolic responses. The horizontal collaborations established throughout this network, together with the provision of a protected environment for early data sharing, will exploit these biological synergies. By interrogating mechanisms that lead from infection to disease, we will be able to develop common vaccine development strategies for these and other complex intracellular pathogens.

Keywords

Tuberculosis, TB, vaccine, leishmaniasis, leprosy, melioidosis, neglected, intracellular



This article is included in the **World TB Day** collection.

Corresponding author: Helen A. Fletcher (Helen.Fletcher@lshtm.ac.uk)

Author roles: **Fletcher HA:** Conceptualization, Funding Acquisition, Writing – Original Draft Preparation, Writing – Review & Editing; **Chatterjee M:** Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Cooper A:** Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Hussell T:** Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Kaye PM:** Conceptualization, Funding Acquisition, Writing – Original Draft Preparation, Writing – Review & Editing; **Prior J:** Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Reljic R:** Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Vermaak S:** Conceptualization, Funding Acquisition, Project Administration, Writing – Original Draft Preparation, Writing – Review & Editing; **Vordermeier M:** Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Williams A:** Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing; **McShane H:** Conceptualization, Funding Acquisition, Writing – Original Draft Preparation, Writing – Review & Editing

Competing interests: Helen McShane and Helen Fletcher are co-investigators on the VALIDATE grant a GCRF/MRC funded Vaccine Network Grant

Grant information: VALIDATE is supported by the Global Challenges Research Fund (GCRF) Networks in Vaccines Research and Development which was co-funded by the MRC and BBSRC. The GCRF is a 5-year £1.5Bn fund established by the UK government. *The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.*

Copyright: © 2018 Fletcher HA *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution Licence](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Fletcher HA, Chatterjee M, Cooper A *et al.* **VALIDATE: Exploiting the synergy between complex intracellular pathogens to expedite vaccine research and development for tuberculosis, leishmaniasis, melioidosis and leprosy [version 1; peer review: 3 approved]** F1000Research 2018, 7:485 (<https://doi.org/10.12688/f1000research.14386.1>)

First published: 23 Apr 2018, 7:485 (<https://doi.org/10.12688/f1000research.14386.1>)

Introduction

The global burden of disease and death caused by *Mycobacterium tuberculosis* (*M.tb*), *Leishmania* spp, *Burkholderia pseudomallei* and *M.leprae* is enormous. Tuberculosis (TB) kills more people than any other infectious disease, with 1.7m deaths and 10.4m new cases in 2016¹. The significant economic impact of TB in low- and middle income countries (LMICs) is due to the disproportionate involvement of the most economically active young adults. Furthermore, bovine TB has a very significant effect on health and economic development in LMIC^{2,3}. The leishmaniasis represent a group of heterogeneous diseases caused by intracellular protozoan parasites of the genus *Leishmania*. They are recognized by the WHO as major neglected diseases of poverty, and disproportionately affect populations in LMICs. Approximately 1.5m new cases occur each year, across 98 countries worldwide, with 20,000–40,000 deaths⁴. Canine visceral leishmaniasis is not only a veterinary problem but a significant reservoir for human disease, notably in Brazil and in countries bordering the Mediterranean. As with TB, leishmaniasis and poverty exist in a vicious circle, with the economic impact for patients, families and communities well documented.

Leprosy and melioidosis also compromise economic productivity in LMICs, are difficult to treat and are in need of effective vaccination strategies. In 2016, there were 216,108 new leprosy cases registered globally⁵. 14 countries contain 95% of these globally reported cases, all of which are in LMICs. Of these, India has the greatest number of cases (59%), followed by Brazil (14%) and Indonesia (8%). Although the number of cases worldwide continues to fall, pockets of high prevalence remain in certain areas such as Brazil, South Asia (India, Nepal, Bhutan), some parts of Africa (Tanzania, Madagascar, Mozambique), and the western Pacific. Melioidosis is a disease caused by the Gram-negative soil-dwelling bacterium *Burkholderia pseudomallei*^{6,7}. The estimated global burden of melioidosis is 165,000 human melioidosis cases/pa, causing 89,000 deaths⁷. The burden of disease is in South East Asia, where the in-hospital mortality is ~40%⁸. These estimates of incidence for leprosy and melioidosis are likely to be significant under-estimates. The development of effective vaccines against any or all of these pathogens would have a significant health benefit around the world.

What does VALIDATE aim to achieve?

The lack of rapid, coordinated dissemination of information between research groups hinders vaccine development. Our strategy is to establish a network of multi-disciplinary scientists across the UK and LMICs, who work on vaccine research and development for these four complex intracellular neglected pathogens. We will take an interdisciplinary approach with immunologists, clinicians, social scientists, veterinarians, epidemiologists, bioinformaticians, mathematical modellers, and animal model experts to overcome barriers to progression of vaccine development. The coordinated, integrated and iterative sharing of data to define protective immunity in animal models, in target animal species, and in human experimental medicine studies, across complex intracellular pathogens will expedite the development of effective vaccines. Our particular focus is on building and

strengthening cross-pathogen, cross-species, cross-discipline and cross-continent collaborations, to foster novel insights and new perspectives that lead to an increased understanding of the nature of protective immunity. Currently, few horizontal collaborations occur between these distinct pathogen research fields. VALIDATE will add value by establishing horizontal collaborations whereby innovative research solutions in one field will be rapidly disseminated to the other fields. This interaction will leverage progress in one field and promote accelerated identification of immune mechanisms of protection and evaluation of vaccine candidates in human and animal models. Given the many common immunological and microbiological features of the complex intracellular pathogens selected as the focus of VALIDATE, these newly-formed horizontal cross-pathogen collaborations will yield novel insights that will be explored iteratively in *in vitro* and *in vivo* experiments in animal models and human experimental medicine studies. For example, a key feature of both TB and leishmaniasis is granuloma formation. Imaging and transcriptomics have been used to define the *Leishmania* granuloma; these techniques could be further used to interpret the TB granuloma^{9,10}.

To date, VALIDATE has 114 members from 24 countries, 17 of these LMICs, and this range of knowledge and experience will broaden our scope and ensure relevance. The VALIDATE members are selected for their complementary scientific expertise and range from internationally recognised leaders in their field to Early Career Researchers (ECRs), with students and members of the general public who are interested in vaccine research also welcome. All scientific members have significant track records in research into TB, leishmaniasis, leprosy or melioidosis. Members can come from academia, governmental organisations, non-profits, and industry. Specific fields of interest include basic immune mechanisms in humans and preclinical animal models, mucosal immunity, immune correlates of protection, immunopathogenesis, translational vaccine development, mathematical modelling and social science aspects of vaccinology.

How will we do it?

VALIDATE has four main activity streams.

Firstly, we are providing relevant funding to our members: as pump-priming grants of £20–50k for innovative collaborative research projects; training grants to enable our ECRs to attend courses, workshops and laboratory exchanges useful for their career progression; and as ECR Fellowships to springboard these Fellows to scientific independence as new group leaders.

Secondly, VALIDATE is developing a dedicated data-sharing portal for members only, which will encourage real-time sharing of data, catalysing the application of insights from one field into another. The VALIDATE Research Data Analyst is tasked with actively searching for data synergies and differences where researchers working on different pathogens can learn from another, and works with members on existing and arising datasets.

Thirdly we provide Continuing Professional Development (CPD) opportunities for our members, including workshops on areas of mutual interest, seminars (that are live-streamed online so that overseas members can also benefit), and a mentoring scheme for ECRs and early PIs open to members across the world – we have linked five mentees with their chosen mentors in our first round. Scientific research is a valuable economic activity to the host country, and we will build sustainable human resource capacity within both the UK and low- and middle-income member countries.

Finally, we are developing a vibrant and interactive network, facilitating the formation of new collaborations and ideas, and speeding the dissemination of useful information amongst our members using the full range of communications tools. We have created a hub website (www.validate-network.org) where our members can easily find information about new research and papers, relevant funding calls, events, and training, mentoring and other opportunities of interest. Interested parties can read about our funded work to date, while a searchable directory of members on our website is facilitating the formation of new collaborations. Our social media (@NetworkValidate) raises awareness of these four pathogens and VALIDATE's research through engagement of members, other scientists and the lay public. An annual meeting, free to all members, furthers our outreach, and boosts existing and potential collaborations. There are travel scholarships available for up to seven LMIC members each year to facilitate the broadest level of attendance.

Summary

VALIDATE provides a unique opportunity for an interdisciplinary and integrated approach to vaccine research and development for these four exemplar complex intracellular neglected pathogens. Sustainable collaborations are being formed and strengthened by the resources provided, innovative research has been funded, and ECR progression is underway. We are using this platform to accelerate vaccine development for our focus pathogens, and are building our funding portfolio to ensure sustained progress in these critical areas.

Data availability

No data is associated with this article.

Competing interests

Helen McShane and Helen Fletcher are co-investigators on the VALIDATE grant a GCRF/MRC funded Vaccine Network Grant.

Grant information

VALIDATE is supported by the Global Challenges Research Fund (GCRF) Networks in Vaccines Research and Development which was co-funded by the MRC and BBSRC. The GCRF is a 5-year £1.5Bn fund established by the UK government.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

- World Health Organization: **Global Tuberculosis Report 2016**. 2017; World Health Organization: Geneva, Switzerland.
[Reference Source](#)
- Ayele WY, Neill SD, Zinsstag J, *et al.*: **Bovine tuberculosis: an old disease but a new threat to Africa**. *Int J Tuberc Lung Dis*. 2004; 8(8): 924–37.
[PubMed Abstract](#)
- Ameni G, Aseffa A, Engers H, *et al.*: **Cattle husbandry in Ethiopia is a predominant factor affecting the pathology of bovine tuberculosis and gamma interferon responses to mycobacterial antigens**. *Clin Vaccine Immunol*. 2006; 13(9): 1030–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Alvar J, Vélez ID, Bern C, *et al.*: **Leishmaniasis worldwide and global estimates of its incidence**. *PLoS One*. 2012; 7(5): e35671.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- World Health Organization: **Fact sheet: Leprosy**. 2018.
[Reference Source](#)
- Peacock SJ, Limmathurotsakul D, Lubell Y, *et al.*: **Melioidosis vaccines: a systematic review and appraisal of the potential to exploit biodefense vaccines for public health purposes**. *PLoS Negl Trop Dis*. 2012; 6(1): e1488.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Limmathurotsakul D, Golding N, Dance DA, *et al.*: **Predicted global distribution of *Burkholderia pseudomallei* and burden of melioidosis**. *Nat Microbiol*. 2016; 1: 15008.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Limmathurotsakul D, Wongratanaheewin S, Teerawattanasook N, *et al.*: **Increasing incidence of human melioidosis in Northeast Thailand**. *Am J Trop Med Hyg*. 2010; 82(6): 1113–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Moore JW, Moyo D, Beattie L, *et al.*: **Functional complexity of the *Leishmania* granuloma and the potential of *in silico* modeling**. *Front Immunol*. 2013; 4: 35.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Beattie L, Sawtell A, Mann J, *et al.*: **Bone marrow-derived and resident liver macrophages display unique transcriptomic signatures but similar biological functions**. *J Hepatol*. 2016; 65(4): 758–768.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Open Peer Review

Current Peer Review Status:   

Version 1

Reviewer Report 26 June 2018

<https://doi.org/10.5256/f1000research.15655.r34153>

© 2018 Reed S. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution Licence](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



Steven G. Reed

Infectious Disease Research Institute, Seattle, WA, USA

Mechanisms of immunity to intracellular pathogens, such as those causing tuberculosis, leishmaniasis, and leprosy have much in common, and as such knowledge in each of these areas should be leveraged and applied as much as possible to these and other intracellular pathogens. The functional definition of CD4 T cell subsets was pioneered in experimental leishmaniasis models and the knowledge has been applied to other infectious diseases, allergy and cancer. Of particular relevance is the selection of vaccine delivery systems and adjuvants that may selectively drive desired immune responses.

Is the topic of the opinion article discussed accurately in the context of the current literature?

Yes

Are all factual statements correct and adequately supported by citations?

Yes

Are arguments sufficiently supported by evidence from the published literature?

Yes

Are the conclusions drawn balanced and justified on the basis of the presented arguments?

Yes

Competing Interests: No competing interests were disclosed.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Reviewer Report 29 May 2018

<https://doi.org/10.5256/f1000research.15655.r34293>

© 2018 Morici L. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution Licence](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



Lisa A. Morici

Tulane University School of Medicine, Department of Microbiology and Immunology, New Orleans, LA, USA

This article comprehensively describes the scope and purpose of VALIDATE, a Global Challenges Research Fund Network. VALIDATE aims to exploit the similarities among complex intracellular bacterial pathogens, including those responsible for tuberculosis, leishmaniasis, melioidosis, and leprosy. Of the target diseases, only tuberculosis receives considerable attention from major funding agencies. Establishment of VALIDATE will help unite researchers from across the globe to accelerate vaccine development against these largely neglected diseases. It will also provide a resource for data sharing, pilot funding, and mentorship for young investigators.

Is the topic of the opinion article discussed accurately in the context of the current literature?

Yes

Are all factual statements correct and adequately supported by citations?

Yes

Are arguments sufficiently supported by evidence from the published literature?

Yes

Are the conclusions drawn balanced and justified on the basis of the presented arguments?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: My area of research focuses on vaccine development against melioidosis.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Reviewer Report 02 May 2018

<https://doi.org/10.5256/f1000research.15655.r33590>

© 2018 Campos-Neto A. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution Licence](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



Antonio Campos-Neto

Detectogen Inc., Westborough, MA, USA

The article reports the goals of the recently created initiative named VALIDATE, which is an organization funded by the Global Challenges Research Fund (GCRF) Networks in Vaccines Research and Development, which is co-funded by the The Medical Research Council (MRC) and The Biotechnology and Biological Sciences Research Council (BBSRC).

VALIDATE is a fantastic Network that aims to promote vaccine research and development for complex intracellular pathogens that cause significant disease burden in low and middle-income countries (LMIC). The authors' summary of VALIDATE activities is outstanding.

The authors and founding members of this much needed initiative deserve the compliments of scientific communities and Government authorities of not only of LMICs but also of developed countries.

One minor suggestion is to add in the article a sentence or two indicating the plans for long term funding sustainability of VALIDATE.

Is the topic of the opinion article discussed accurately in the context of the current literature?

Yes

Are all factual statements correct and adequately supported by citations?

Yes

Are arguments sufficiently supported by evidence from the published literature?

Yes

Are the conclusions drawn balanced and justified on the basis of the presented arguments?

Yes

Competing Interests: No competing interests were disclosed.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research